A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin Resistant Pathogens
Sign Up to like & getrecommendations! Published in 2020 at "ACS Infectious Diseases"
DOI: 10.1021/acsinfecdis.0c00223
Abstract: Semisynthetic rifamycin derivatives such as rifampicin (Rif) are first line treatments for tuberculosis and other bacterial infections. Historically, synthetic modifications made to the C-3/C-4 region of the rifamycin naphthalene core, like those seen in Rif,… read more here.
Keywords: semisynthetic kanglemycin; efficacy high; shows vivo; kanglemycin shows ... See more keywords